A new subgroup analysis from the Phase 3 VESALIUS-CV trial reveals that Amgen’s Repatha reduces the risk of first major cardiovascular events by 31% in high-risk patients without known atherosclerosis.
Amgen‘s cholesterol-lowering medication Repatha® (evolocumab) dramatically reduces the risk of a first major adverse cardiovascular event (MACE) in high-risk patients by 25%, according to groundbreaking [Read More…]
The U.S. Food and Drug Administration (FDA) has broadened the approved use of Amgen’s Repatha (evolocumab) for adults at increased risk for major adverse cardiovascular events (MACE) due to uncontrolled low-density lipoprotein cholesterol (LDL-C).
